Additionally, it has been found an enrichment of CD163+CD33+PD-L1+ TAMs in tumors from hyper-progressor patients in comparison with patients not experiencing hyper-progression strongly suggests the spatial distribution of TAMs plays an important role in determining the outcome of patients with NSCLC treated with ICIs [134]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.